Dr. Kraitchman's research interests are concentrated on non-invasive imaging and minimally invasive treatment of cardiovascular disease. She has been actively involved in developing new methods to image myocardial function and perfusion using MRI. Current research interests are aimed at determining the optimal timing and method of administration of mesenchymal stem cells to regenerate infarcted myocardium using non-invasive MR fluoroscopic delivery and imaging. MRI and radiolabeling techniques include novel MR and radiotracer stem cell labeling methods to determine the location, quantity and biodistribution of stem cells after delivery as well as to noninvasively determine the efficacy of these therapies in acute myocardial infarction and peripheral arterial disease.
Recently, the first technique to provide radiopaque labeling of stem cells for x-ray fluoroscopic delivery and CT imaging of stem cell persistence for cardiac and peripheral arterial disease applications has been developed. These labeling techniques have been developed using FDA-approved contrast agents in large animal preclinical models of cardiovascular disease using clinical MR, radionuclide and CT imaging scanners for rapid translation to the clinical realm. She is also focused on the development of new animal models of human disease for noninvasive imaging studies and the development of promising new therapies in clinical trials for companion animals.
The Kraitchman lab concentrates on clinical translation of minimally invasive imaging technology that uses new molecular imaging and nanomedicine techniques to enable stem cell tracking and enhanced engraftment. Recent research efforts in the lab have concentrated on developing x-ray visible stem cells for cardiovascular applications. Using multimodality imaging techniques, the research team confirms stem cell viability with PET and bioluminescence. Then, using conventional devices currently in clinical trials, Kraitchman's researchers image and target stem cells to the heart directly using MRI fluoroscopy with a specialized MRI-compatible device or x-ray fluoroscopic imager.
Lab Website: Dara Kraitchman Laboratory
Technology Expertise Keywords
Stem cell, veterinary imaging, cardiovascular, MRI, CT, PET, SPECT
Clinical Trial Keywords
obesity embolization interventional radiology
veterinary clinical trials
View all on Pubmed
Krimins R, Fritz J,Gainsburg L, Gavin P, Ihms EZ, Huso DL, Kraitchman DL. MR-Guided bone biopsy of a T11 vertebral body mass in a Rottweiler. J Amer Vet Med Assoc,2017 250(7):779-784
Weiss, CR, Akinwande O, Paudel K, Cheskin LJ, Holly B, Hong K, Fischman AM, Patel RS, Shin EJ, Steele KE, Moran TH, Kaiser K, Park A, Shade DM, Kraitchman DL, Arepally A. Clinical safety of bariatric arterial embolization: Preliminary results of the BEAT Obesity Trial, Radiology.2017 May;283(2):598-608.
Kraitchman D, Kamel I, Weiss C and Georgiades C. Elucidation of percutaneously accessible lymph nodes in swine: A large animal model for interventional lymphatic research. J Vasc Interv Radiol. 2017; 28:451–456
Lauer AM, El-Sharkawy AM, Kraitchman DL, Edelstein WA. "MRI acoustic noise can harm experimental and companion animals." J Magn Reson Imaging. 2012 Sep;36(3):743-7. doi: 10.1002/jmri.23653.
Fu Y, Azene N, Ehtiati T, Flammang A, Gilson WD, Gabrielson K, Weiss CR, Bulte JW, Johnston PV, Kraitchman DL :X-ray fusion with magnetic resonance image-guidance of intrapericardial delivery of microencapsulated human mesenchymal stem cells in immunocompetent swine. Radiology, 2014 272(2):427-437.